Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**L-AP4** is a small molecule, synthetic, non-proteinogenic amino acid that acts as a potent and selective **agonist for the group III metabotropic glutamate receptors** (mGluR4, mGluR6, mGluR7, and mGluR8)[1][3][9][11]. It works by binding presynaptically to these receptors—primarily in the central nervous system—where it functions to suppress glutamate release and depress synaptic transmission in glutamatergic pathways, including the hippocampus, olfactory bulb, and retina[9][4]. It is widely used as a research tool to probe the function of group III mGluRs, but it is not approved for therapeutic or diagnostic use in humans[11].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on L-AP4.